Heart failure

Patients with congestive heart failure may be eligible for treatment that could help them live longer

Patients diagnosed with moderate aortic stenosis and congestive heart failure can qualify to participate in a national clinical trial that includes the Memorial Cardiac and Vascular Institute and will determine if minimally invasive valve replacement benefits those currently receiving only treatment. with medication.

HOLLYWOOD, Florida., August 18, 2022 /PRNewswire-PRWeb/ — Patients diagnosed with moderate aortic stenosis and congestive heart failure can qualify to participate in a clinical trial that will determine whether minimally invasive valve replacement benefits those who are currently treated only with medications.

The procedure, known by the acronym “TAVR” (Replacement of the aortic valve by catheter), is currently only approved for use in patients with severe aortic stenosis. In these cases, the aortic valve is replaced through a transcatheter process that replaces open-heart surgery and has allowed individuals to feel better, avoid hospital stays, and live longer.

To date, TAVR has not been approved as an option for people with moderate aortic stenosis. These patients are currently receiving medical treatment and are followed by guideline-directed medical treatment until their condition worsens. The National ‘TAVR UNLOAD’ Trial Memorial Heart and Vascular Institute is involved in investigating whether performing the valve replacement much earlier, before the patient’s condition worsens, provides the same benefits.

“The exciting part for the patient in the TAVR trial is potentially having access to a treatment that otherwise would not be available to them,” said dr. jonathan robert, Medical Director of Clinical Research and Education, Interventional Cardiology for Memorial Health System and Director of its Cardiology Fellowship Program. “TAVR is an amazing procedure that we do quite frequently, but it’s new for us to do it on those whose disease hasn’t progressed to its later stages.”

The clinical trial will randomize patients with moderate aortic stenosis, with 50% receiving the TAVR procedure and the other half continuing with traditional medical treatment. The researchers expect the five-year comparative study to produce results that demonstrate whether those who underwent the procedure earlier achieve the same benefits as those who undergo TAVI once their heart disease becomes more severe and how these results compare to those who continued with guideline-directed medical treatment. “Memorial’s participation in the trial is a direct result of the healthcare system’s ascension as an academic medical center with the expertise and patient volumes required for host institutions,” said Dr. Roberts.

Those diagnosed with congestive heart failure and moderate aortic stenosis may be eligible to participate in the TAVR UNLOAD trial, which is currently accepting applicants who meet specific medical criteria. To inquire about eligibility, contact Memorial’s Office of Human Research at 954-265-1847.

# # #

The Memorial Cardiac & Vascular Institute is a leader in cardiovascular care, offering a wide range of services dedicated to the prevention, detection and treatment of cardiovascular disease. Its multidisciplinary specialists work together using sophisticated diagnostic equipment and facilities. Outcomes of cardiovascular care are regularly reviewed by committees of physicians and nurses to provide quality assurance using computerized data collection.

For more information on Total Cardiac Care, you can visit them at mhs.net/services/cardiac-vascular.

Media Contact

Kerting Baldwin, Ed.D., APR, Memorial Healthcare System, 954.265.1136, [email protected]

SOURCE Memorial Cardiac and Vascular Institute